Our product portfolio

A broad range of pharmaceuticals, devices and supplies for modern healthcare.

Products under registration

  • MediCure-OncoX

    Under registration

    Novel small molecule inhibitor for advanced solid tumors. Registration in progress.

  • NeuroPath-Rx

    Under registration

    First-in-class therapy for early-stage Alzheimer's disease. Currently in Phase III review.

  • CardioFlow+

    Under registration

    Improved formulation for hypertension management with enhanced patient compliance.

Our future product pipeline

  1. 2025

    Gene Therapy

    Launch of our first gene-editing therapeutic for rare genetic diseases.

  2. 2026

    AI-Driven Diagnostics

    Integration of AI into diagnostic platforms for precision medicine.

  3. 2027

    Personalized Medicine

    Development of bespoke drug delivery systems tailored to individual patient profiles.

  4. 2028

    Regenerative Medicines

    Expansion into regenerative therapies for tissue repair and organ regeneration.

Let’s build a reliable supply partnership

Tell us what your facility needs and our team will get back to you.

Talk to our team